SCHEMBL5651267

SCHEMBL5651267

O=C(NCc1cccnc1)c1ccc(-c2nc3ccc(C(F)(F)F)cc3[nH]2)s1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SORT1 Q99523 1/20 0.52
DGAT1 O75907 1/20 0.50
KCNH2 Q12809 1/20 0.50
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
NPBWR1 P48145 2/20 0.41
NAMPT P43490 2/20 0.41
KIT P10721 1/20 0.41
SCD O00767 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDR P35968 1/20 0.41
CBFB Q13951 1/20 0.41
SLC40A1 Q9NP59 1/20 0.41
FLT3 P36888 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651274 0.93 SORT1 (0.52) SORT1DGAT1KCNH2MAPTSMN1; SMN2
SCHEMBL5648735 0.82 NPSR1 (0.43) SMN1; SMN2ALDH1A1LMNAHTTNAMPT
SCHEMBL5648741 0.82 NPSR1 (0.43) SMN1; SMN2ALDH1A1LMNAHTTNAMPT
SCHEMBL5653471 0.79 HTT (0.47) MAPTALDH1A1LMNAHTTSLC40A1
SCHEMBL5651260 0.77 DGAT1 (0.48) SORT1DGAT1KCNH2MAPTSMN1; SMN2
SCHEMBL5648366 0.75 ACKR3 (0.47) DGAT1KCNH2MAPTSMN1; SMN2ALDH1A1
SCHEMBL5653423 0.75 TSHR (0.44) MAPTALDH1A1LMNAHTTNAMPT
SCHEMBL5653421 0.75 TSHR (0.44) ALDH1A1LMNAHTTNAMPTNPSR1
SCHEMBL5649026 0.73 DGAT1 (0.43) DGAT1KCNH2NPBWR1CBFB
SCHEMBL5651069 0.73 MEN1 (0.51) DGAT1KCNH2MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 SORT1 4615/4885DGAT1 2386/4885KCNH2 3319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.